News & Updates

Show Multimedia Only
Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC

Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC

16 Aug 2023

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

16 Aug 2023
Modified-dose nirmatrelvir-ritonavir well tolerated, effective in advanced CKD patients

Modified-dose nirmatrelvir-ritonavir well tolerated, effective in advanced CKD patients

15 Aug 2023 byChristina Lau

Modified-dose regimens of nirmatrelvir-ritonavir are well tolerated and effective in COVID-19 patients with advanced chronic kidney disease (CKD), including those on dialysis, a study by the Chinese University of Hong Kong (CUHK) has shown.

15 Aug 2023